NO985739D0 - Generering av molekyler som er replikative in vivo - Google Patents

Generering av molekyler som er replikative in vivo

Info

Publication number
NO985739D0
NO985739D0 NO985739A NO985739A NO985739D0 NO 985739 D0 NO985739 D0 NO 985739D0 NO 985739 A NO985739 A NO 985739A NO 985739 A NO985739 A NO 985739A NO 985739 D0 NO985739 D0 NO 985739D0
Authority
NO
Norway
Prior art keywords
vivo
generation
molecules
replicative
replicative molecules
Prior art date
Application number
NO985739A
Other languages
English (en)
Norwegian (no)
Other versions
NO985739L (no
Inventor
Michel Perricaudet
Patrice Yeh
Hul Ne Leblois-Prehaud
Original Assignee
Rh Ne Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rh Ne Poulenc Rorer Sa filed Critical Rh Ne Poulenc Rorer Sa
Publication of NO985739D0 publication Critical patent/NO985739D0/no
Publication of NO985739L publication Critical patent/NO985739L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
NO985739A 1996-06-12 1998-12-08 Generering av molekyler som er replikative in vivo NO985739L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9607273A FR2749857B1 (fr) 1996-06-12 1996-06-12 Generation de molecules replicatives in vivo
PCT/FR1997/000914 WO1997047757A1 (fr) 1996-06-12 1997-05-23 Generation de molecules replicatives in vivo

Publications (2)

Publication Number Publication Date
NO985739D0 true NO985739D0 (no) 1998-12-08
NO985739L NO985739L (no) 1998-12-08

Family

ID=9492965

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985739A NO985739L (no) 1996-06-12 1998-12-08 Generering av molekyler som er replikative in vivo

Country Status (18)

Country Link
US (1) US6630322B1 (de)
EP (1) EP0906443B1 (de)
JP (1) JP2000511779A (de)
AT (1) ATE301721T1 (de)
AU (1) AU726442B2 (de)
BR (1) BR9709700A (de)
CA (1) CA2257916A1 (de)
CZ (1) CZ296600B6 (de)
DE (1) DE69733948T2 (de)
DK (1) DK0906443T3 (de)
ES (1) ES2248849T3 (de)
FR (1) FR2749857B1 (de)
HU (1) HU224175B1 (de)
IL (1) IL127430A0 (de)
NO (1) NO985739L (de)
SK (1) SK169898A3 (de)
WO (1) WO1997047757A1 (de)
ZA (1) ZA975134B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU2001288839A1 (en) * 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
WO2003004088A2 (en) 2001-07-05 2003-01-16 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
EP2362912A1 (de) * 2008-11-14 2011-09-07 Life Technologies Corporation Zusammensetzungen und verfahren zur zellmanipulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
EP0632054A1 (de) * 1993-06-28 1995-01-04 European Molecular Biology Laboratory Regulation stellenspezifischer Rekombination mittels stellungsspezifischer Rekombinase/Kernrezeptor-Fusionsproteine
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
EP0927263A1 (de) * 1996-01-05 1999-07-07 Genetic Therapy, Inc. Rekombinase-vermittelte herstellung adenoviraler vektoren

Also Published As

Publication number Publication date
US6630322B1 (en) 2003-10-07
ATE301721T1 (de) 2005-08-15
EP0906443A1 (de) 1999-04-07
CZ296600B6 (cs) 2006-04-12
DE69733948T2 (de) 2006-06-08
CA2257916A1 (fr) 1997-12-18
FR2749857B1 (fr) 1998-08-14
BR9709700A (pt) 1999-08-10
DE69733948D1 (de) 2005-09-15
EP0906443B1 (de) 2005-08-10
FR2749857A1 (fr) 1997-12-19
ES2248849T3 (es) 2006-03-16
DK0906443T3 (da) 2005-12-19
WO1997047757A1 (fr) 1997-12-18
JP2000511779A (ja) 2000-09-12
HUP9902585A3 (en) 2001-11-28
CZ402398A3 (cs) 1999-03-17
SK169898A3 (en) 1999-07-12
ZA975134B (en) 1997-12-31
AU3037797A (en) 1998-01-07
NO985739L (no) 1998-12-08
HUP9902585A2 (hu) 1999-11-29
HU224175B1 (hu) 2005-06-28
IL127430A0 (en) 1999-10-28
AU726442B2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
DE69635931D1 (de) Komplementäre adenovirenvektorsysteme und zellinien
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE288480T1 (de) Chondrogene in vitro induktion von menschlichen mensenchymalen stammzellen
WO2000017771A3 (de) Verfahren zum konfigurieren eines konfigurierbaren hardware-blocks
DK0906443T3 (da) Generering af replikerende molekyler in vivo
DE69933653D1 (de) Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen
ES2161066T3 (es) Procedimiento para la obtencion de polimeros de estireno expandibles.
NO20002504L (no) Adenovirusvektorer og fremgangsmÕte for Õ redusere homologe rekombinasjonsfenomener
YU5800A (sh) Univerzalno primenljiva krvna plazma
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
AU1520701A (en) Segmented process for cleaning-in-place
DE60118798D1 (de) Fragmente der intron a von citomegalovirus
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2002097056A3 (en) Method for generating replication defective viral vectors that are helper free
MX9305913A (es) Polipeptidos implicados en la biosintesis de las estreptograminas, secuencias nucleotidicas que las codifican, procedimiento para su produccion y procedimiento para la obtencion de las estreptograminas.
ATE343329T1 (de) Verfahren zum herstellen von parboiled reis und charge von parboiled reis
DE69834283D1 (de) Vorrichtung zur Zurückgewinnung, Raffination und Speicherung von Wasserstoffgas
WO1998018950A3 (de) Aav-dna mit helfervirus-sequenzen
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
DE69834422D1 (de) Klonierungsverfahren durch multiple verdauung
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
ZA200307708B (en) Method and apparatus for generating context-descriptive messages.
ATE318893T1 (de) Verbesserte replikation von hcv rna

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application